RU2020114781A - Новые молочнокислые бактерии и их применение - Google Patents
Новые молочнокислые бактерии и их применение Download PDFInfo
- Publication number
- RU2020114781A RU2020114781A RU2020114781A RU2020114781A RU2020114781A RU 2020114781 A RU2020114781 A RU 2020114781A RU 2020114781 A RU2020114781 A RU 2020114781A RU 2020114781 A RU2020114781 A RU 2020114781A RU 2020114781 A RU2020114781 A RU 2020114781A
- Authority
- RU
- Russia
- Prior art keywords
- mental illness
- proteobacteria
- neurological mental
- neurological
- group
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims 6
- 208000020016 psychiatric disease Diseases 0.000 claims 25
- 244000005700 microbiome Species 0.000 claims 23
- 230000000926 neurological effect Effects 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 17
- 230000000968 intestinal effect Effects 0.000 claims 13
- 238000003745 diagnosis Methods 0.000 claims 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 10
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims 8
- 241000186604 Lactobacillus reuteri Species 0.000 claims 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 7
- 241000186000 Bifidobacterium Species 0.000 claims 6
- 241000588921 Enterobacteriaceae Species 0.000 claims 5
- 241000186660 Lactobacillus Species 0.000 claims 5
- 235000014655 lactic acid Nutrition 0.000 claims 5
- 239000004310 lactic acid Substances 0.000 claims 5
- 241001156739 Actinobacteria <phylum> Species 0.000 claims 4
- 241000605059 Bacteroidetes Species 0.000 claims 4
- 241001135755 Betaproteobacteria Species 0.000 claims 4
- 241001135761 Deltaproteobacteria Species 0.000 claims 4
- 241001148568 Epsilonproteobacteria Species 0.000 claims 4
- 241000192125 Firmicutes Species 0.000 claims 4
- 241000192128 Gammaproteobacteria Species 0.000 claims 4
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 210000003608 fece Anatomy 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 238000004445 quantitative analysis Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 241000588749 Klebsiella oxytoca Species 0.000 claims 1
- 241001468157 Lactobacillus johnsonii Species 0.000 claims 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 241000588772 Morganella morganii Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229940076266 morganella morganii Drugs 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000012175 pyrosequencing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
Claims (23)
1. Молочнокислая бактерия, выделенная из экскрементов.
2. Молочнокислая бактерия по п. 1, где молочнокислая бактерия представляет собой Lactobacillus reuteri NK33 (KCCM12090P) или Bifidobacterium adolescentis NK98 (KCCM12297P).
3. Молочнокислая бактерия по п. 2, где Lactobacillus reuteri NK33 (KCCM12090P) содержит последовательность 16S рДНК под SEQ ID NO: 1.
4. Молочнокислая бактерия по п. 2, где Bifidobacterium adolescentis NK98 (KCCM12297P) содержит последовательность 16S рДНК под SEQ ID NO: 38.
5. Фармацевтическая композиция для предупреждения или лечения неврологического психического заболевания, содержащая Lactobacillus reuteri NK33 (KCCM12090P), Bifidobacterium adolescentis NK98 (KCCM12297P) или их смесь.
6. Фармацевтическая композиция по п. 5, предназначенная для предупреждения или лечения неврологического психического заболевания, где Lactobacillus reuteri NK33 (KCCM12090P) или Bifidobacterium adolescentis NK98 (KCCM12297P) является живой бактериальной клеткой, инактивированной бактериальной клеткой, ее культурой, лизатом или экстрактом.
7. Фармацевтическая композиция по п. 5, предназначенная для предупреждения или лечения неврологического психического заболевания, где неврологическое психическое заболевание представляет собой нейродегенеративное заболевание или психическое расстройство.
8. Фармацевтическая композиция по п. 7, предназначенная для предупреждения или лечения неврологического психического заболевания, где психическое расстройство представляет собой одно или более расстройств, выбранных из группы, включающей тревожность, депрессию, расстройство настроения, инсомнию, бредовое расстройство, обсессивное расстройство, мигрень, стресс, расстройство памяти, когнитивное расстройство и нарушение внимания.
9. Фармацевтическая композиция по п. 7, предназначенная для предупреждения или лечения неврологического психического заболевания, где нейродегенеративное заболевание представляет собой одно или более заболеваний, выбранных из группы, включающей болезнь Паркинсона, болезнь Хантингтона, болезнь Альцгеймера, боковой амиотрофический склероз, спиноцеребеллярную атрофию, синдром Туретта, атаксию Фридрейха, болезнь Мачадо-Джозефа, деменцию, дистонию и прогрессирующий надъядерный паралич.
10. Фармацевтическая композиция по п. 5, предназначенная для предупреждения или лечения неврологического психического заболевания, где фармацевтическая композиция дополнительно содержит Bifidobacterium adolescentis IM38 (KCCM11807P).
11. Функциональный оздоровительный пищевой продукт для предупреждения или улучшения в отношении неврологического психического заболевания, содержащий Lactobacillus reuteri NK33 (KCCM12090P), Bifidobacterium adolescentis NK98 (KCCM12297P) или их смесь.
12. Фармацевтическая композиция для предупреждения или лечения воспалительного заболевания, содержащая Lactobacillus reuteri NK33 (KCCM12090P), Bifidobacterium adolescentis NK98 (KCCM12297P) или их смесь.
13. Функциональный оздоровительный пищевой продукт для предупреждения или улучшения в отношении воспалительного заболевания, содержащий Lactobacillus reuteri NK33 (KCCM12090P), Bifidobacterium adolescentis NK98 (KCCM12297P) или их смесь.
14. Композиция для диагностики неврологического психического заболевания, содержащая средство для измерения уровня микроорганизма кишечника, где микроорганизм кишечника представляет собой один или более микроорганизмов, выбранных из группы, включающей Bacteroidetes, Actinobacteria, Firmicutes, Bifidobacteria, Lactobacilli, β-Рroteobacteria, δ-Рroteobacteria, γ-Рroteobacteria, ε-Рroteobacteria и Enterobacteriaceae.
15. Композиция по п. 14, предназначенная для диагностики неврологического психического заболевания, где композиция обеспечивает возможность диагностики неврологического психического заболевания, если повышен уровень одного или более микроорганизмов, выбранных из группы микроорганизмов кишечника, включающей β-Рroteobacteria, δ-Рroteobacteria, γ-Рroteobacteria, ε-Рroteobacteria и Enterobacteriaceae.
16. Композиция по п. 15, предназначенная для диагностики неврологического психического заболевания, где микроорганизм из семейства Enterobacteriaceae представляет собой один или более микроорганизмов, выбранных из группы, включающей Klebsiella oxytoca, Escherichia coli и Morganella morganii.
17. Композиция по п. 14, предназначенная для диагностики неврологического психического заболевания, где композиция обеспечивает возможность диагностики неврологического психического заболевания, если снижен уровень какого-либо из микроорганизмов, выбранных из группы микроорганизмов кишечника, включающей Bacteroidetes, Actinobacteria, Firmicutes, Bifidobacteria и Lactobacilli.
18. Композиция по п. 17, предназначенная для диагностики неврологического психического заболевания, где микроорганизм из рода Lactobacilli представляет собой один или более микроорганизмов, выбранных из группы, включающей Lactobacillus reuteri, Lactobacillus johnsonii и Lactobacillus rhamnosus, и микроорганизм из рода Bifidobacteria представляет собой Bifidobacterium animalis.
19. Композиция по п. 14, предназначенная для диагностики неврологического психического заболевания, где композиция обеспечивает возможность диагностики неврологического психического заболевания, если повышен уровень одного или более микроорганизмов, выбранных из группы микроорганизмов кишечника, включающей β-Рroteobacteria, δ-Рroteobacteria, γ-Рroteobacteria, ε-Рroteobacteria и Enterobacteriaceae; и если снижен уровень какого-либо из микроорганизмов кишечника, выбранных из группы, включающей Bacteroidetes, Actinobacteria, Firmicutes, Bifidobacteria и Lactobacilli.
20. Композиция по п. 14, предназначенная для диагностики неврологического психического заболевания, где средство представляет собой праймер или зонд, обеспечивающие возможность измерения уровня конкретного гена микроорганизма кишечника; антитело или аптамер, обеспечивающее возможность измерения уровня белка, экспрессирующегося с конкретного гена; праймер или зонд для количественного анализа последовательности 16S рДНК микроорганизма кишечника или средство для пиросеквенирования для количественного анализа последовательности геномной ДНК микроорганизма кишечника.
21. Композиция по п. 14, предназначенная для диагностики неврологического психического заболевания, где композиция дополнительно содержит средство для измерения количества липополисахарида (LPS).
22. Набор для диагностики неврологического психического заболевания, содержащий композицию по любому из пп. 14-21.
23. Информативный способ диагностики неврологического психического заболевания, предусматривающий стадию измерения уровня микроорганизма кишечника, выделенного из экскрементов индивидуума с подозрением на неврологическое психическое заболевание; и стадию сравнения уровня микроорганизма кишечника с уровнем микроорганизма кишечника в экскрементах контрольной группы, отличной от группы с неврологическим психическим заболеванием, где микроорганизм кишечника представляет собой один или более микроорганизмов, выбранных из группы, включающей Bacteroidetes, Actinobacteria, Firmicutes, Bifidobacteria, Lactobacilli, β-Рroteobacteria, δ-Рroteobacteria, γ-Рroteobacteria, ε-Рroteobacteria и Enterobacteriaceae.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170127422 | 2017-09-29 | ||
| KR10-2017-0127422 | 2017-09-29 | ||
| PCT/KR2018/011607 WO2019066599A2 (ko) | 2017-09-29 | 2018-09-28 | 신규 유산균 및 이의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022114567A Division RU2022114567A (ru) | 2017-09-29 | 2018-09-28 | Новые молочнокислые бактерии и их применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020114781A true RU2020114781A (ru) | 2021-10-29 |
| RU2020114781A3 RU2020114781A3 (ru) | 2021-10-29 |
| RU2776223C2 RU2776223C2 (ru) | 2022-07-14 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| EP3715448A2 (en) | 2020-09-30 |
| AU2021282468A1 (en) | 2022-01-06 |
| AU2018341753A1 (en) | 2020-03-26 |
| JP7307216B2 (ja) | 2023-07-11 |
| CN116286509A (zh) | 2023-06-23 |
| NZ762407A (en) | 2023-09-29 |
| CA3199327A1 (en) | 2019-04-04 |
| CA3063669A1 (en) | 2019-04-04 |
| MX2020003198A (es) | 2020-10-12 |
| AU2021282468B2 (en) | 2023-10-05 |
| SG11201911984QA (en) | 2020-01-30 |
| RU2020114781A3 (ru) | 2021-10-29 |
| CN111465684B (zh) | 2023-03-31 |
| WO2019066599A2 (ko) | 2019-04-04 |
| KR20210064173A (ko) | 2021-06-02 |
| JP7038202B2 (ja) | 2022-03-17 |
| CN111465684A (zh) | 2020-07-28 |
| AU2018341753B2 (en) | 2021-11-18 |
| BR112020005747A2 (pt) | 2020-10-13 |
| WO2019066599A3 (ko) | 2019-05-23 |
| SG10201913043TA (en) | 2020-03-30 |
| KR20190038451A (ko) | 2019-04-08 |
| JP2020534853A (ja) | 2020-12-03 |
| KR20220004233A (ko) | 2022-01-11 |
| JP2022071102A (ja) | 2022-05-13 |
| EP3715448A4 (en) | 2021-06-30 |
| CA3063669C (en) | 2023-08-01 |
| KR102348851B1 (ko) | 2022-01-12 |
| KR102260489B1 (ko) | 2021-06-04 |
| KR102655293B1 (ko) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Gut microbiota in patients with Parkinson's disease in southern China | |
| Cabrera-Rubio et al. | Impact of mode of delivery on the milk microbiota composition of healthy women | |
| Candela et al. | Unbalance of intestinal microbiota in atopic children | |
| Leite et al. | Assessment of the microbial diversity of Brazilian kefir grains by PCR-DGGE and pyrosequencing analysis | |
| Kostic et al. | The microbiome in inflammatory bowel disease: current status and the future ahead | |
| Turpin et al. | Lactobacillaceae and cell adhesion: genomic and functional screening | |
| Fujimoto et al. | Identification and quantification of viable Bifidobacterium breve strain Yakult in human faeces by using strain‐specific primers and propidium monoazide | |
| Petricevic et al. | Characterisation of the oral, vaginal and rectal Lactobacillus flora in healthy pregnant and postmenopausal women | |
| Shao et al. | Lactobacillus plantarum HNU082-derived improvements in the intestinal microbiome prevent the development of hyperlipidaemia | |
| JP2019508479A (ja) | 中枢神経系の精神障害または疾患を処置するための腸ミクロビオームの改変 | |
| EP1997906A1 (en) | Lactobacillus | |
| Zommiti et al. | Probiotic characteristics of Lactobacillus curvatus DN317, a strain isolated from chicken ceca | |
| Andoh et al. | Faecal microbiota profile of Crohn’s disease determined by terminal restriction fragment length polymorphism analysis | |
| Rohani et al. | Highly heterogeneous probiotic Lactobacillus species in healthy Iranians with low functional activities | |
| Duary et al. | Expression of the atpD gene in probiotic Lactobacillus plantarum strains under in vitro acidic conditions using RT-qPCR | |
| Zawistowska-Rojek et al. | Assessment of the microbiological status of probiotic products | |
| Desfossés-Foucault et al. | Dynamics and rRNA transcriptional activity of lactococci and lactobacilli during Cheddar cheese ripening | |
| Kenfack et al. | Safety and antioxidant properties of five probiotic Lactobacillus plantarum strains isolated from the digestive tract of honey bees | |
| Delgado et al. | Identification of dominant bacteria in feces and colonic mucosa from healthy Spanish adults by culturing and by 16S rDNA sequence analysis | |
| Türk et al. | Coryneform bacteria in human semen: inter-assay variability in species composition detection and biofilm production ability | |
| Huang et al. | The probiotic and immunomodulation effects of Limosilactobacillus reuteri RGW1 isolated from calf feces | |
| van Bokhorst‐van de Veen et al. | Genotypic adaptations associated with prolonged persistence of Lactobacillus plantarum in the murine digestive tract | |
| RU2020114781A (ru) | Новые молочнокислые бактерии и их применение | |
| Gulcin et al. | Probable novel probiotics: Eps production, cholesterol removal and glycocholate deconjugation of lactobacillus plantarum ga06 and ga11 isolated from local handmade-cheese | |
| Waters et al. | Characterisation of prototype Nurmi cultures using culture-based microbiological techniques and PCR-DGGE |